Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | S37C |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | CTNNB1 S37C lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37C results in proliferation similar to wild-type Ctnnb1 (PMID: 33987379), however, results in nuclear accumulation of Ctnnb1 (PMID: 12754743, PMID: 10433945) and increased cell migration (PMID: 33987379), and therefore, is predicted to lead to a gain of Ctnnb1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 act mut CTNNB1 S37C |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41224622C>G |
cDNA | c.110C>G |
Protein | p.S37C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001098209.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.41224622C>G | c.110C>G | p.S37C | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 S37C | lung non-small cell carcinoma | predicted - resistant | Osimertinib | Case Reports/Case Series | Actionable | In a retrospective analysis, activating CTNNB1 mutations including S37F/C (n=5), D32V (n=1), G34V (n=1), and T41I (n=1) were identified in 8 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416). | 31839416 |
CTNNB1 S37C | hepatocellular carcinoma | sensitive | WNTinib | Preclinical - Cell culture | Actionable | In a preclinical study, WNTinib inhibited Ezh2 phosphorylation and viability in a hepatocellular carcinoma cell line harboring CTNNB1 S37C in culture (PMID: 37537299). | 37537299 |